Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance

Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Amphotericin B and Flucytosine

(2012) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

DifferentialIn VivoActivities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and withoutFKSResistance Mutations

(2012) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Changes in Incidence and Antifungal Drug Resistance in Candidemia: Results From Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008-2011

(2012) A. A. Cleveland et al.   CLINICAL INFECTIOUS DISEASES

The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012

(2012) Nkechi Azie et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008

(2012) Michael Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey

(2012) J. Peman et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata

(2012) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Candida guilliermondii and Other Species of Candida Misidentified as Candida famata: Assessment by Vitek 2, DNA Sequencing Analysis, and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry in Two Global Antifungal Surveillance Programs

(2012) Mariana Castanheira et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012

(2012) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme

(2012) Michael A. Pfaller et al.   MYCOPATHOLOGIA

Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria

(2011) Michael A. Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

(2011) M.A. Pfaller et al.   DRUG RESISTANCE UPDATES

Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes

(2011) S. A. Grim et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Current issues in the clinical management of invasive candida infections - the AGIHO, DMykG, ÖGMM and PEG web-based survey and expert consensus conference 2009

(2011) M. Karthaus et al.   MYCOSES

Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains

(2010) M. Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epidemiology of invasive candidiasis

(2010) Maiken C Arendrup   Current Opinion in Critical Care

Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009)

(2010) Michael A. Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods

(2010) M.A. Pfaller et al.   DRUG RESISTANCE UPDATES

Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009

(2010) A. Bueid et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies

(2010) A. Alanio et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Breakthrough Invasive Candidiasis in Patients on Micafungin

(2010) C. D. Pfeiffer et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)

(2010) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)

(2010) A. Espinel-Ingroff et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Acquired antifungal drug resistance inAspergillus fumigatus:epidemiology and detection

(2010) Susan Julie Howard et al.   MEDICAL MYCOLOGY

In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?

(2010) Susanne Perkhofer et al.   Current Infectious Disease Reports

Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species

(2009) M. C. Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins andCandidaspp.

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance Network

(2009) J. W. Baddley et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatus

(2008) J. L. Rodriguez-Tudela et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts

(2008) J.L. Rodriguez-Tudela et al.   CLINICAL MICROBIOLOGY AND INFECTION

Infections Caused by Scedosporium spp.

(2008) K. J. Cortez et al.   CLINICAL MICROBIOLOGY REVIEWS

Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods

(2008) A. Alastruey-Izquierdo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Sequence-Based Identification of Aspergillus, Fusarium, and Mucorales Species in the Clinical Mycology Laboratory: Where Are We and Where Should We Go from Here?

(2008) S. A. Balajee et al.   JOURNAL OF CLINICAL MICROBIOLOGY